Sugi Predict

Sugi Predict / Compounds / SCHEMBL2939811

SCHEMBL2939811

SCHEMBL2939811

CC1C(=O)N(c2ccc(OC(F)(F)F)cc2)C(=O)N1Cc1ccncc1C(=O)N(C)C

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 1/20 0.42
▸ SMO Q99835 4/20 0.36
▸ SLC6A2 P23975 1/20 0.35
▸ SLC6A4 P31645 1/20 0.35
▸ MAPT P10636 1/20 0.33
▸ TP53 P04637 1/20 0.33
▸ EPHX2 P34913 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ HCRTR1 O43613 3/20 0.33
▸ HCRTR2 O43614 2/20 0.33
▸ LIPE Q05469 1/20 0.33
▸ TEAD1 P28347 1/20 0.33
▸ TEAD4 Q15561 1/20 0.33
▸ TEAD2 Q15562 1/20 0.33
▸ TEAD3 Q99594 1/20 0.33
▸ CHRM4 P08173 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2940256 0.90 IGF1R (0.42) IGF1RSMOTP53LIPETEAD1
SCHEMBL2938020 0.90 IGF1R (0.44) IGF1RSMOTP53EPHX2POLB
SCHEMBL2941293 0.89 ORAI1 (0.39) IGF1RMAPTTP53POLBHCRTR1
SCHEMBL2938328 0.89 IGF1R (0.43) IGF1RSMOTP53EPHX2POLB
SCHEMBL2936267 0.89 SMO (0.41) IGF1RSMOMAPTL3MBTL1
SCHEMBL2941303 0.88 IGF1R (0.42) IGF1RSMOMAPTTP53EPHX2
SCHEMBL2940556 0.88 IGF1R (0.42) IGF1RSMOSLC6A2SLC6A4TP53
SCHEMBL3730971 0.88 IGF1R (0.42) IGF1RSMOTP53EPHX2POLB
SCHEMBL2940552 0.86 IGF1R (0.43) IGF1RSMOTP53EPHX2POLB
SCHEMBL2932724 0.86 IGF1R (0.45) IGF1RSMOTP53HCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825115-B2 Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-11-02 — — US disclosed
EP-1599464-B1 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2010-09-22 — — EP disclosed
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-08 — — US disclosed
US-7354933-B2 Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate AVENTIS PHARMA SA (FR) 2008-04-08 — — US disclosed
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2004-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors PRKG1, PRKACA, CMPK1 IGF1R 1595/4885SMO 2187/4885SLC6A2 4745/4885
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors PRKG1, PRKACA, PRKCA IGF1R 962/4885SMO 2697/4885SLC6A2 4677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.